X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Allyson Funk

Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience includes leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.

Recent Posts

The risks of counterfeit imported medicines

By Allyson Funk  |    April 20, 2017
A recent Wall Street Journal article laid out the serious concerns posed by potent, counterfeit prescription opioids pouring into the United States from China, Mexico and Canada. The Drug...   Read More

Medicare Monday: A guide to MedPAC’s Part B vote this week

By Allyson Funk  |    April 3, 2017
The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises Congress on issues related to the Medicare program, including payment, access to and quality...   Read More

ICYMI: What the experts are saying about importation

By Allyson Funk  |    March 23, 2017
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have...   Read More

Medicare Monday: Billing code basics for biologics in Part B

By Allyson Funk  |    March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would...   Read More

How drug importation schemes could increase U.S. law enforcement burdens

By Allyson Funk  |    March 16, 2017
In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?   Read More

Why drug importation threatens patient safety

By Allyson Funk  |    February 28, 2017
Counterfeit drug manufacturing and trafficking is a multi-billion dollar business. Legislative proposals to allow importation of potentially counterfeit and substandard drugs into the United...   Read More

Fact Check Friday: The truth about drug importation and patient safety

By Allyson Funk  |    February 24, 2017
This week on Fact Check Friday, we’re discussing the truth about proposals to allow the importation of medicines from other countries and what these proposals mean for patients. MYTH: Importation...   Read More

What you don’t know about importation from Canada

By Allyson Funk  |    February 17, 2017
Proposals to allow the importation of prescription medicines from Canada ignore the dangerous threat to patients of counterfeit and adulterated medicines. What actually happens when a patient...   Read More

Medicare Monday: Negotiation in Medicare Part D works

By Allyson Funk  |    December 12, 2016
Earlier this year, we highlighted a new QuintilesIMS Institute research brief that, for the first time, looked at Part D costs after accounting for rebates.   Read More

Medicare Monday: Beware! Scary proposed changes to Medicare are out there

By Allyson Funk  |    October 31, 2016
This Halloween, beware of the spooky proposals some have put forward to change how Medicare covers prescription medicines for seniors and people living with disabilities. Tricks like these are no...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates